Authors/Disclosures
|
David Rog, MBBS
|
Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Rog has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. Dr. Rog has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Rog has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck. Dr. Rog has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neuraxpharm. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Rog has received research support from Merck. The institution of Dr. Rog has received research support from Novartis. The institution of Dr. Rog has received research support from TG Therapeutics. Dr. Rog has received research support from Janssen-Cilag. |
|
Julie M. Jiang
|
No disclosure on file |
|
Ayse S. Tinaz, MD, PhD
(Yale Department of Neurology)
|
The institution of Dr. Tinaz has received research support from NINDS/NIH. |
|
Glen A. Cook, Jr., MD, FAAN
|
Dr. Cook has stock in Aspire Biopharma. An immediate family member of Dr. Cook has stock in Aspire Biopharma. |
|
Laurent Vernillet
|
No disclosure on file |
|
Turo Nurmikko, MD, PhD
(Pain Research Institute)
|
No disclosure on file |
|
Nathan Tagg, MD
(Duke Eye Center)
|
Dr. Tagg has stock in Apple, Birkshire Hathaway, Medtronic. |
|
Carolyn Young
(Biogen UK)
|
No disclosure on file |
|
|
No disclosure on file |